ROSTELECOM PJSC: ROSTELECOM FINANCIAL AND -4-
DJ ROSTELECOM PJSC: ROSTELECOM FINANCIAL AND OPERATING RESULTS FOR THE FIRST QUARTER 2021
ROSTELECOM PJSC (RKMD)
ROSTELECOM PJSC: ROSTELECOM FINANCIAL AND OPERATING RESULTS FOR THE FIRST QUARTER 2021
13-May-2021 / 09:30 MSK
Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014
(MAR), transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
= ROSTELECOM FINANCIAL AND OPERATING RESULTS FOR THE FIRST QUARTER 2021
First quarter revenue increased by 9%; OIBDA[1] up 18%; net profit up 58% and FCF[2] increases by RUB 8.4 billion.
Moscow, Russia - May 13, 2021 - Rostelecom PJSC (MOEX: RTKM, RTKMP; OTCQX: ROSYY), the largest digital service provider
CREDIT AGRICOLE SA: Results for the first quarter 2021 – STRONG ACTIVITY, SOLID RESULTS padovanews.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from padovanews.it Daily Mail and Mail on Sunday newspapers.
ALD: Trading update on Q1 2021 results
DJ ALD: Trading update on Q1 2021 results
ALD
ALD: Trading update on Q1 2021 results
06-May-2021 / 07:30 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=
Press release
Paris, 6 May 2021
Trading update on Q1 2021 results - NET INCOME (GROUP SHARE) UP 20.7% VS Q1 2020 - VERY STRONG USED CAR SALES RESULT PER UNIT AT EUR 439 AND A RECORD VOLUME OF USED CAR SALES AT 87K UNITS - IMPROVING COST INCOME (EXCL UCS) RATIO AT 49.9% - STRONG PERFORMANCE CONFIRMING 2021 OUTLOOK - TOTAL CONTRACTS[1] STABLE AT 1.76 MILLION - ACQUISITION OF BANSABADELL RENTING (SPAIN) - c. 20K VEHICLES
DJ ALD: Trading update on Q1 2021 results ALD ALD: Trading update on Q1 2021 results 06-May-2021 / 07:30 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021
Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical centers
Five partnered allogeneic CAR-T product candidates in clinical development through our collaborations with Allogene and Servier: UCART19/ALLO-501 and ALLO-501A in r/r NHL, ALLO-715 and ALLO-605 in r/r MM and ALLO-316 in advanced or metastatic clear cell renal cell carcinoma
New collaboration with Cytovia Therapeutics, Inc. to develop TALEN
®
Successful for UCART product candidates; On track to start production of UCART product candidates in 2021